Logo for TFF Pharmaceuticals Inc

TFF Pharmaceuticals Investor Relations Material

Latest events

Logo for TFF Pharmaceuticals Inc

Study Update

TFF Pharmaceuticals
Logo for TFF Pharmaceuticals

Q2 2024

14 Aug, 2024
Logo for TFF Pharmaceuticals

Q1 2024

14 May, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from TFF Pharmaceuticals Inc

Access all reports
TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing, or TFF, technology platform. The company is developing TFF-Pharma's lead product candidate, TFF-100, a pharmacologically active inhaled dry powder-based fibrosis therapy for the treatment of idiopathic pulmonary fibrosis (IPF) and cystic fibrosis. It owns and has control over the molecule (SMART-Breathe), formulation design, regulatory pathway data from previous phase 1 clinical trials in humans, development milestones and timelines, human safety data from phase 1 clinical trials that can be leveraged for future regulatory activities with health authorities worldwide for the development of the SMART-Breathe formulation for use in the treatment of IPF and CF. The company was founded in 2018 and is headquartered in Austin, Texas.